152 related articles for article (PubMed ID: 12377651)
21. Non-seminomatous germ cell testicular tumours: residual masses after chemotherapy.
Levitt MD; Reynolds PM; Sheiner HJ; Byrne MJ
Br J Surg; 1985 Jan; 72(1):19-22. PubMed ID: 2578300
[TBL] [Abstract][Full Text] [Related]
22. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours.
Hartmann JT; Candelaria M; Kuczyk MA; Schmoll HJ; Bokemeyer C
Eur J Cancer; 1997 May; 33(6):843-7. PubMed ID: 9291803
[TBL] [Abstract][Full Text] [Related]
23. Survival of patients with viable malignant non-seminomatous germ cell tumour persistent after cisplatin-based induction chemotherapy.
Hollender A; Stenwig EA; Ous S; Fosså SD
Eur Urol; 1997; 31(2):141-7. PubMed ID: 9076455
[TBL] [Abstract][Full Text] [Related]
24. Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group.
Fosså SD; Droz JP; Stoter G; Kaye SB; Vermeylen K; Sylvester R
Br J Cancer; 1995 Mar; 71(3):619-24. PubMed ID: 7880748
[TBL] [Abstract][Full Text] [Related]
25. [Treatment of metastatic germ cell tumors with etoposide and cisplatin as first line chemotherapy].
Shintaku I; Numahata K; Suzuki K; Ohyama C; Sato M; Saito S; Hoshi S; Orikasa S
Nihon Hinyokika Gakkai Zasshi; 2002 May; 93(4):519-24. PubMed ID: 12056035
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant chemotherapy after orchiectomy in high-risk patients with clinical stage I non-seminomatous testicular cancer.
Studer UE; Fey MF; Calderoni A; Kraft R; Mazzucchelli L; Sonntag RW
Eur Urol; 1993; 23(4):444-9. PubMed ID: 7687549
[TBL] [Abstract][Full Text] [Related]
27. Delayed orchiectomy after chemotherapy in patients with advanced testicular cancer.
Ondrus D; Hornák M; Breza J; Mat'oska J; Schnorrer M; Belan V; Kausitz J
Int Urol Nephrol; 2001; 32(4):665-7. PubMed ID: 11989561
[TBL] [Abstract][Full Text] [Related]
28. Histological outcome of delayed orchidectomy after primary chemotherapy for metastatic germ cell tumour of the testis.
Ramani VA; Grey BR; Addla SK; Dunham MP; Sangar VK; Clarke NW
Clin Oncol (R Coll Radiol); 2008 Apr; 20(3):247-52. PubMed ID: 18093814
[TBL] [Abstract][Full Text] [Related]
29. Routine computerised tomographic scans of the thorax in surveillance of stage I testicular non-seminomatous germ-cell cancer--a necessary risk?
Harvey ML; Geldart TR; Duell R; Mead GM; Tung K
Ann Oncol; 2002 Feb; 13(2):237-42. PubMed ID: 11886000
[TBL] [Abstract][Full Text] [Related]
30. Non-germ cell malignancy in residual or recurrent mass after chemotherapy for nonseminomatous testicular germ cell tumor.
Lutke Holzik MF; Hoekstra HJ; Mulder NH; Suurmeijer AJ; Sleijfer DT; Gietema JA
Ann Surg Oncol; 2003 Mar; 10(2):131-5. PubMed ID: 12620907
[TBL] [Abstract][Full Text] [Related]
31. Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature.
Porcaro AB; Antoniolli SZ; Maffei N; Beltrami P; Bassetto MA; Curti P
Arch Ital Urol Androl; 2002 Jun; 74(2):81-5. PubMed ID: 12161942
[TBL] [Abstract][Full Text] [Related]
32. Disease relapse in patients with stage I nonseminomatous germ cell tumor of the testis on active surveillance.
Thompson PI; Nixon J; Harvey VJ
J Clin Oncol; 1988 Oct; 6(10):1597-603. PubMed ID: 2459319
[TBL] [Abstract][Full Text] [Related]
33. Results of adjuvant surgery in patients with stage III and IV nonseminomatous testicular tumors after cisplatin-vinblastine-bleomycin chemotherapy.
Gelderman WA; Schraffordt Koops H; Sleijfer DT; Oosterhuis JW; Van der Heide JN; Mulder NH; Marrink J; De Bruyn HW; Oldhoff J
J Surg Oncol; 1988 Aug; 38(4):227-32. PubMed ID: 2457771
[TBL] [Abstract][Full Text] [Related]
34. [Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors].
Müller-Mattheis V; Reinhardt M; Gerharz CD; Fürst G; Vosberg H; Müller-Gärtner HW; Ackermann R
Urologe A; 1998 Nov; 37(6):609-20. PubMed ID: 9887489
[TBL] [Abstract][Full Text] [Related]
35. Early clinical stages of nonseminomatous testis cancer. Evaluation of the primary treatment and follow-up procedures of the SWENOTECA project.
Klepp O; Olsson AM; Ous S; Nilsson S; Høisaether PA; Tveter K
Scand J Urol Nephrol; 1991; 25(3):179-90. PubMed ID: 1658924
[TBL] [Abstract][Full Text] [Related]
36. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
[TBL] [Abstract][Full Text] [Related]
37. Excision of residual masses after platinum based chemotherapy for non-seminomatous germ cell tumours.
Harding MJ; Brown IL; MacPherson SG; Turner MA; Kaye SB
Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1689-94. PubMed ID: 2561098
[TBL] [Abstract][Full Text] [Related]
38. Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT).
de Bono JS; Paul J; Simpson A; Anthoney A; Kirk D; Underwood M; Graham J; Kaye SB
Br J Cancer; 2000 Aug; 83(4):426-30. PubMed ID: 10945485
[TBL] [Abstract][Full Text] [Related]
39. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors.
Motzer RJ; Sheinfeld J; Mazumdar M; Bajorin DF; Bosl GJ; Herr H; Lyn P; Vlamis V
J Clin Oncol; 1995 Nov; 13(11):2700-4. PubMed ID: 7595727
[TBL] [Abstract][Full Text] [Related]
40. Predictive factors for the histologic nature of residual tumor mass after chemotherapy in patients with advanced testicular cancer.
Matsuyama H; Yamamoto N; Sakatoku J; Suga A; Hayashida S; Kamiryo Y; Nagata K; Naito K
Urology; 1994 Sep; 44(3):392-8; discussion 398-9. PubMed ID: 8073552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
